NL-OMON52526招募中不适用
From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients - HepBTer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1) Age 18 - 60 years
- •2) Proven chronic hepatitis B (CHB) for more than 6 months, based on serology
- •(HBsAg positivity) and at screening a viral load of:
- •i) Group A: HBV DNA >=200 IU/mL and <20,000 IU/mL
- •ii) Group B: HBV DNA < 20 IU/mL
- •3) HBeAg-positive and -negative CHB patients
- •4) No current use of any antiviral medication (group A) or currently treated
- •with tenofovir only.
- •5) Normal liver function, assessed by:
- •i) Fibroscan of <= 7.0 kiloPascal (kPa)
- •ii) Alanine aminotransferase (ALT) and/or aspirate aminotransferase (AST) at
- •screening <= 1.25 x upper limit of normal (ULN)
- •iii) Thrombocytes 150-400 10E9/L
- •iv) Total bilirubin 0-17 µmol/L (elevated levels may be accepted if
- •unconjugated portion is elevated in patients with Gilbert syndrome)
- •v) Albumin within normal value (35 - 50 g/L)
- •vi) Prothrombin Time (PT) within normal value (9,5 - 12.5 sec)
- •vii) Alkaline phosphatase (ALP) and Gamma-glutamyltransferase (GGT) within
- •normal values (40-120 U/L and 0-40 U/L respectively)
- •6) Body mass index (BMI): 17.0-35.0 kg/m2
- •7) Clinical chemistry, hematologic and coagulation tests at screening must be
- •within normal limits or clinically non-significant, as by the investigators
- •assessment.
- •8) At screening, women of child bearing potential must be non-pregnant and
- •non-lactating proven by negative urine or serum pregnancy test at screening.
- •9) Female patients of child-bearing potential (with a fertile male sexual
- •partner) and male patients (if not surgically sterilized) must be willing to
- •use adequate contraception from screening until last study visit.
- •10) At screening, has no recent (<3 months) history of any clinically
- •significant conditions, which, in the opinion of the investigator, would
- •jeopardize the safety of the subject or impact the validity of the study
- •11) Voluntary written informed consent must be obtained before any study
- •related interventions (including screening and enrollment) can be conducted.
排除标准
- •1) Currently active, or a history of liver cirrhosis determined by one or more
- •of the following:
- •i) Liver biopsy;
- •ii) Elastography (e.g. Fibroscan);
- •iii) Combination of usual radiological and biochemical criteria
- •2) Currently active, liver disease other than CHB
- •3) Co-infection with HCV, HDV, HEV and/or HIV
- •4) Acute HAV at screening
- •5) Renal impairment (estimated glomerular filtration rate (eGRF) < 60ml/min)
- •6) Currently active, or a history of: psoriasis or lupus erythematodes
- •7) Use of oral medication that interacts with the liver metabolism enzyme
- •CYP2D6, or which is known to be hepatotoxic or otherwise known to interact with
- •terbinafine (such as rifampicine).
- •8) Usage or plans to receive systemic immunosuppressive or immunomodulating
- •medications (e.g. IFN) during the study or <= 4 months prior to the first
- •investigational product administration.
- •9) Clinical diagnosis of substance abuse <= 12 months prior to screening with
- •narcotics or cocaine or with alcohol (regular consumption > 14 units/week [men]
- •and > 7 units/week [women])
- •10) Inability to understand the patient information and make an informed
- •decision to participate
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate the safety and efficacy of terbinafine for chronic infection of the liver with the hepatitis B virus.Chronic hepatitis B infectionMedDRA version: 20.0Level: LLTClassification code 10052552Term: Hepatitis B virusSystem Organ Class: 100000004848MedDRA version: 20.1Level: LLTClassification code 10047450Term: Viral hepatitis BSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10019737Term: Hepatitis B carrierSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-003419-68-NLAcademic Medical Center (AMC)26
招募中
1 期
The First Clinical Trial of Bacteriophage Therapy in Patients wtih Acne VulgarisAcneJPRN-jRCTs051230164Tsuruta Daisuke15
已完成
不适用
Safety and tolerability of ABNCoV2SARS-CoV-2, COVID-19NL-OMON20987Stichting Radboud universitair medisch centrum45
已完成
不适用
First-in-human trial of the Coronavirus virus-like particle subunit vaccine ABNCoV2 in SARS-CoV-2-naïve adult volunteers in good health (COUGH-1)NL-OMON50898Radboud Universitair Medisch Centrum45
尚未招募
3 期
agos COVID-19 Black Seed Oil Trial (LACBSOT)COVID-19PACTR202007611764617agos State Government80